CDK7 thus makes an interesting potential target for anti‐cancer therapies and the agent ICEC0942 is shown to be a potent CDK7‐specific inhibitor in both ER‐positive and TNBC cell lines.133. The gene discussed is CDK7; the disease is cancer.